<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03580382</url>
  </required_header>
  <id_info>
    <org_study_id>17-00363</org_study_id>
    <nct_id>NCT03580382</nct_id>
  </id_info>
  <brief_title>Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma</brief_title>
  <official_title>Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celldex Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of this study is to test if it is safe and effective to give CDX-3379 together&#xD;
      to treat advanced melanoma in patients with the NRAS mutation and BRAF/NRAS wildtype.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      Phase 1b: To determine the RP2D and assess the toxicity and tolerability of the combination&#xD;
      of CDX-3379 (ERBB3 antibody) and trametinib (MEK inhibitor) in NRAS and BRAF/NRAS WT melanoma&#xD;
      patients&#xD;
&#xD;
      Phase 2: To estimate the response rates and duration of response of the combination of&#xD;
      CDX-3379 (ERBB3 antibody) and trametinib in NRAS positive and BRAF/NRAS WT melanoma patients&#xD;
&#xD;
      Secondary/Exploratory Objectives:&#xD;
&#xD;
      Phase 1b: To assess clinical activity and steady-state pharmacokinetics of CDX-3379 and&#xD;
      trametinib Phase 2: To compare the efficacy of the combination of CDX-3379 (ERBB3 antibody)&#xD;
      and trametinib is more effective than a MEK inhibitor alone in NRAS positive and BRAF/NRAS WT&#xD;
      melanoma patients alone using locally assessed progression free survival (PFS) and overall&#xD;
      survival (OS).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Per regulatory coordinator, the sponsor is no longer supporting the study.&#xD;
  </why_stopped>
  <start_date type="Actual">July 6, 2018</start_date>
  <completion_date type="Actual">September 26, 2018</completion_date>
  <primary_completion_date type="Actual">September 26, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>48 Months</time_frame>
    <description>response rate, will be compared with the historically reported response rate for the single agent trametinib in NRAS and BRAF/NRAS WT melenoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>48 Months</time_frame>
    <description>Survival data will be collectedvia telephone or clinic visits every 3 months (+10 days) from the date of last treatment, and median will be estimated using Kaplan-Meier approach</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>NRAS mutant melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>WT melanoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trametinib daily Until PD</intervention_name>
    <description>1.0 mg daily</description>
    <arm_group_label>NRAS mutant melanoma</arm_group_label>
    <arm_group_label>WT melanoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX-3379 (ERBB3 antibody)</intervention_name>
    <description>15mg/kg IV Q3W</description>
    <arm_group_label>NRAS mutant melanoma</arm_group_label>
    <arm_group_label>WT melanoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Read, understood, and provided written informed consent and, if applicable, Health&#xD;
             Insurance Portability and Accountability Act (HIPAA) authorization after the nature of&#xD;
             the study has been fully explained and must be willing to comply with all study&#xD;
             requirements and procedures.&#xD;
&#xD;
             2. Male or female patients who are 18 years of age or older. 3. Patients with a&#xD;
             diagnosis of histologically confirmed advanced (defined as unresectable stage III or&#xD;
             IV) melanoma with the NRAS Q61 mutation or BRAF/NRAS WT for which there is no&#xD;
             remaining standard therapy with curative potential or patients are ineligible or&#xD;
             unable to tolerate therapy with curative potential.&#xD;
&#xD;
               -  Any standard of care mutation testing is acceptable to document mutation status.&#xD;
&#xD;
                  4.Patients must have archival tissue and at least one disease site amenable to&#xD;
                  biopsy:&#xD;
&#xD;
               -  For phase Ib, all patients will undergo fresh tumor biopsy&#xD;
&#xD;
               -  For phase II, five patients with NRAS mutation and five patients with BRAF/NRAS&#xD;
                  WT melanoma will undergo fresh tumor biopsy 5.Measurable (target) disease by&#xD;
                  Response Evaluation Criteria In Solid Tumors (RECIST 1.1) criteria. Target&#xD;
                  lesions selected for tumor measurements should be those where additional (eg&#xD;
                  palliative) treatments are not indicated or anticipated.&#xD;
&#xD;
               -  Measurable disease per RECIST 1.1 requirements: defined as longest diameter to be&#xD;
                  recorded for non-nodal lesions &gt; 10mm and short axis for nodal lesions &gt;15 mm&#xD;
                  using conventional techniques 6.All residual toxicity related to prior&#xD;
                  radiotherapy or anticancer therapies (excluding alopecia, grade 2 fatigue,&#xD;
                  vitiligo or endocrinopathies on stable replacement therapy) must resolve to grade&#xD;
                  1 severity or less (or returned to baseline) prior to receipt of study treatment.&#xD;
&#xD;
                  7.Adequate electrolytes, liver, renal, and hematology function as defined below:&#xD;
&#xD;
                  a.Hemoglobin ≥ 9 g/dL b.Absolute neutrophil count ≥ 1500/mm3 c.Platelet count ≥&#xD;
                  100,000/mm3 d.Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&#xD;
                  ≤ 2.5 × upper limit of normal (ULN) (≤ 5 × ULN for cases involving liver&#xD;
                  metastasis) e.Bilirubin ≤ 1.5 × ULN (≤ 5 × ULN for cases of documented or&#xD;
                  suspected Gilbert's disease) f.Serum creatinine ≤ 1.5 g/dL or calculated&#xD;
                  creatinine clearance (CrCl) ≥60 mL/min for patients with serum creatinine &gt; 1.5 x&#xD;
                  ULN g.Serum magnesium, calcium and potassium within normal limits 8.Life&#xD;
                  expectancy ≥ 12 weeks 9.ECOG performance status (PS) &lt; 1 10.Willing and able to&#xD;
                  comply with scheduled visits, treatment plan, and laboratory tests.&#xD;
&#xD;
                  11.Screening EKG without clinically significant abnormalities. 12.Corrected&#xD;
                  (Fridericia's) QTcF must be &lt; 480 milliseconds. 13.Allowance of prior therapy&#xD;
                  regimens:&#xD;
&#xD;
               -  No limit on prior number of regimens&#xD;
&#xD;
               -  Must have completed prior cytotoxic chemotherapy a minimum of 4 weeks prior to&#xD;
                  starting study treatment (except for bis-chlorethynitrosurea (BCNU)), which must&#xD;
                  have been completed a minimum of 6 weeks prior to starting therapy.&#xD;
&#xD;
               -  Prior localized radiation therapy must have been completed a minimum of 2 weeks&#xD;
                  prior to starting therapy and the patient must have baseline imaging with a full&#xD;
                  body PET-CT or CT scans of the chest, abdomen, and pelvis and within 4 weeks&#xD;
                  prior to study enrollment.&#xD;
&#xD;
               -  For CNS metastases, disease must be treated and demonstrate stability with Brain&#xD;
                  MRI a minimum of 2 weeks prior to starting therapy.&#xD;
&#xD;
                  14.Both male and female patients enrolled in this trial must agree to use highly&#xD;
                  effective contraception during the course of the trial and for at least for 6&#xD;
                  months after the final dose of CDX-3379 (an effective form of contraception is an&#xD;
                  oral contraceptive or a double barrier method), or greater, as in accordance with&#xD;
                  the label requirements for trametinib. Patients and/or partners who are&#xD;
                  surgically sterile or postmenopausal are exempt from this requirement.&#xD;
&#xD;
               -  Women of child-bearing potential, defined as all women physiologically capable of&#xD;
                  becoming pregnant, unless they are using highly effective methods of&#xD;
                  contraception during dosing and for 3 months after stopping study drug. Highly&#xD;
                  effective contraception methods include:&#xD;
&#xD;
               -  Total abstinence or&#xD;
&#xD;
               -  Male or female sterilization or&#xD;
&#xD;
               -  Combination of any two of the following (a+b or a+c or b+c):&#xD;
&#xD;
                    1. Use of oral, injected or implanted hormonal methods of contraception;&#xD;
                       hormonal contraceptives are not acceptable as a sole method of&#xD;
                       contraception.&#xD;
&#xD;
                    2. Placement of an intrauterine device (IUD) or intrauterine system (IUS)&#xD;
&#xD;
                    3. Barrier methods of contraception: condom or occlusive cap (diaphragm or&#xD;
                       cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal&#xD;
                       suppository 15. Women are considered post-menopausal and not of child&#xD;
                       bearing potential if they have had 12 months of natural (spontaneous)&#xD;
                       amenorrhea with an appropriate clinical profile (e.g. age appropriate,&#xD;
                       history of vasomotor symptoms) or have had surgical bilateral oophorectomy&#xD;
                       (with or without hysterectomy) or tubal ligation at least six weeks ago. In&#xD;
                       the case of oophorectomy alone, only when the reproductive status of the&#xD;
                       woman has been confirmed by follow up hormone level assessment is she&#xD;
                       considered not of child bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Received CDX-3379 or other anti-ErbB3 targeted agents previously.&#xD;
&#xD;
          2. Received trametinib or other MEK inhibitor agents previously.&#xD;
&#xD;
          3. Any concurrent chemotherapy, radiotherapy, immunotherapy, biologic or hormonal therapy&#xD;
             for cancer treatment. Concurrent use of hormones for non-cancer related conditions&#xD;
             (e.g., insulin for diabetes and hormone replacement therapy) is acceptable.&#xD;
&#xD;
          4. Other prior malignancy active within 2 years, except for localized prostate cancer,&#xD;
             cervical carcinoma in situ, non-melanomatous carcinoma of the skin, stage 1&#xD;
             differentiated thyroid cancer or ductal carcinoma in situ of the breast that has/have&#xD;
             undergone curative surgery or radiation.&#xD;
&#xD;
          5. Active central nervous system (CNS) metastases are excluded. Known brain metastases&#xD;
             must have been previously treated and asymptomatic for 2 weeks and not progressive in&#xD;
             size or number for 4 weeks prior to enrollment, documented via scans. Continued use of&#xD;
             anticonvulsants (in the absence of any suspicion of progressive brain metastases) is&#xD;
             acceptable. Patients must currently be on a stable, lowest possible dose of steroids.&#xD;
&#xD;
          6. Radiation therapy within 14 days prior to the first scheduled dose in this study,&#xD;
             including, in addition (if necessary), the timeframe for resolution of any actual or&#xD;
             anticipated toxicities from such radiation.&#xD;
&#xD;
          7. Known HIV, hepatitis B or hepatitis C infection, or active infection requiring&#xD;
             systemic intravenous therapy&#xD;
&#xD;
          8. Use of any monoclonal based therapies within 4 weeks (excluding cetuximab which does&#xD;
             not require a wash-out), and all other immunotherapy (tumor vaccine, cytokine, or&#xD;
             growth factor given to control the cancer) within 2 weeks, prior to the first dose of&#xD;
             study treatment.&#xD;
&#xD;
          9. Chemotherapy within 4 weeks (except for bis-chlorethynitrosurea (BCNU), which must&#xD;
             have been completed a minimum of 6 weeks) prior to starting therapy.&#xD;
&#xD;
         10. Major surgery within 4 weeks prior to the first dose of study treatment. Surgery&#xD;
             requiring local/epidural anesthesia must be completed at least 72 hours before study&#xD;
             drug administration and patients should be recovered.&#xD;
&#xD;
         11. Use of other investigational drugs within 2 weeks or 5 half-lives (whichever is&#xD;
             longer) prior to study treatment administration&#xD;
&#xD;
         12. A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;450 ms); additional risk factors for torsades de pointes (TdP) (e.g., a&#xD;
             history of heart failure, family history of Long QT Syndrome, or active hypokalemia or&#xD;
             uncorrectable electrolyte abnormality); significant cardiovascular disease including&#xD;
             unstable angina pectoris, uncontrolled hypertension or arrhythmia, congestive heart&#xD;
             failure (New York Heart Association Class III or IV) related to primary cardiac&#xD;
             disease, uncontrolled ischemic or severe valvular heart disease; or any of the&#xD;
             following within 6 months prior to the first dose of study treatment: myocardial&#xD;
             infarction, severe/unstable angina, coronary artery bypass graft, congestive heart&#xD;
             failure, cerebrovascular accident, transient ischemic attack.&#xD;
&#xD;
         13. Requirement for chronic immunosuppressive medication including systemic&#xD;
             corticosteroids above the physiologic dose (defined as 20 mg/day prednisone or the&#xD;
             equivalent).&#xD;
&#xD;
         14. Any other acute or chronic medical or psychiatric condition or laboratory abnormality&#xD;
             that could increase the risk associated with trial participation or trial drug&#xD;
             administration or could interfere with the interpretation of trial results and, in the&#xD;
             judgment of the investigator, would make the patient inappropriate for entry into the&#xD;
             trial.&#xD;
&#xD;
         15. Known alcohol or drug abuse.&#xD;
&#xD;
         16. Sexually active males must use a condom during intercourse while taking the drug and&#xD;
             for 3 months after stopping study drug and should not father a child in this period. A&#xD;
             condom is required to be used also by vasectomized men in order to prevent delivery of&#xD;
             the drug via seminal fluid.&#xD;
&#xD;
         17. Inability to swallow pills&#xD;
&#xD;
         18. Patients unwilling or unable to comply with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Weber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 9, 2018</study_first_posted>
  <results_first_submitted>May 12, 2020</results_first_submitted>
  <results_first_submitted_qc>May 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 20, 2020</results_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/82/NCT03580382/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NRAS Mutant Melanoma</title>
          <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
        </group>
        <group group_id="P2">
          <title>WT Melanoma</title>
          <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Early Termination of Study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The study was terminated before more participants could be enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>NRAS Mutant Melanoma</title>
          <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
        </group>
        <group group_id="B2">
          <title>WT Melanoma</title>
          <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="0"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>response rate, will be compared with the historically reported response rate for the single agent trametinib in NRAS and BRAF/NRAS WT melenoma</description>
        <time_frame>48 Months</time_frame>
        <population>Study was terminated prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>NRAS Mutant Melanoma</title>
            <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
          </group>
          <group group_id="O2">
            <title>WT Melanoma</title>
            <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>response rate, will be compared with the historically reported response rate for the single agent trametinib in NRAS and BRAF/NRAS WT melenoma</description>
          <population>Study was terminated prior to analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Survival data will be collectedvia telephone or clinic visits every 3 months (+10 days) from the date of last treatment, and median will be estimated using Kaplan-Meier approach</description>
        <time_frame>48 Months</time_frame>
        <population>Study was terminated prior to analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>NRAS Mutant Melanoma</title>
            <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
          </group>
          <group group_id="O2">
            <title>WT Melanoma</title>
            <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Survival data will be collectedvia telephone or clinic visits every 3 months (+10 days) from the date of last treatment, and median will be estimated using Kaplan-Meier approach</description>
          <population>Study was terminated prior to analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Short duration of study prior to termination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>WT Melanoma</title>
          <description>C1D1-C1D21, CDX-3379 D1Trametinib daily Biopsy (days 14-16)&#xD;
Trametinib daily Until PD: 1.0 mg daily&#xD;
CDX-3379 (ERBB3 antibody): 15mg/kg IV Q3W</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rachael Keller, Sr. Regulatory Specialist</name_or_title>
      <organization>NYU Langone Health - PCC CTO</organization>
      <phone>929-455-2453</phone>
      <email>Rachael.Keller@nyulangone.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

